Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02846571 · ClinicalTrials.gov registry record · Phase 1

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

A Phase 1 study of Diabetes, sponsored by Midhat H. Abdulreda.

Recruiting
Registry status
Phase 1
Development phase
2
Enrollment target
2
Study locations

NCT02846571 is a Phase 1 study of Diabetes that is actively recruiting participants, run by Midhat H. Abdulreda. The registered enrollment target is 2 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02846571, a Phase 1 study of Diabetes, is actively recruiting participants, sponsored by Midhat H. Abdulreda.

RECRUITING
Registry status
Phase 1
Development phase
2 participants
Enrollment target
2
Study locations

Study Summary

The intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take approximately 20-30 minutes. Transplant recipients in this study will receive localized maintenance immunosuppression via topical application of eye-drops.

Conditions Studied

Interventions

  • BIOLOGICAL Human Pancreatic Islet Transplantation

Study Locations (2)

Florida

  • Bascom Palmer Eye Institute - Miami
  • Diabetes Research Institute, University of Miami Miller School of Medicine - Miami

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2019-12-05
Est. Completion 2027-12-31
Phase Phase 1

Sponsor

Midhat H. Abdulreda

1 total trials

What the Registry Record Tells You About NCT02846571

The ClinicalTrials.gov registry entry for NCT02846571 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (100% lower). The listed sponsor is Midhat H. Abdulreda, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Human Pancreatic Islet Transplantation is the first listed.

NCT02846571 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT02846571 about?

NCT02846571 is a clinical study titled "Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye". The intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take ap...

What is the current status of trial NCT02846571?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-12-05. Estimated completion is 2027-12-31.

What conditions does trial NCT02846571 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT02846571?

The interventions under investigation include: Human Pancreatic Islet Transplantation (BIOLOGICAL).

Who is sponsoring clinical trial NCT02846571?

This trial is sponsored by Midhat H. Abdulreda, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02846571 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.